ImmunoGen’s First ADC For Ovarian Cancer To Exceed Sales Expectations
Stellar Launch For Elahere
Executive Summary
ImmunoGen’s Elahere, the only antibody-drug conjugate approved for platinum-resistant ovarian cancer in the US, will produce better than anticipated sales for the first quarter of 2023, CEO Mark Enyedy hinted in a recent interview.
You may also be interested in...
AbbVie Spends $10bn On ImmunoGen To Improve Chances In ADC Space
Despite writing down $4bn after the failure of Stemcentrx’s Rova-T, AbbVie will bet big again on the cancer antibody-drug conjugate space by paying a high premium for ImmunoGen, including Elahere and its R&D potential.
Finance Watch: Lucky Few Raise Cash While Many Public Biotechs Cut Costs
Public Company Edition: ImmunoGen received the first $75m under a $175m term loan, while Protagonist raised $100m in a follow-on offering, but companies with bankruptcy filings and job cuts outpaced those accessing new capital by a wide margin in late March and early April.
ADCs Coming Of Age: Deals, Targets And Catalysts
The antibody-drug conjugate field is beginning to reach its full potential and big pharma’s attention has been caught.